Clinical Trials Logo

Radiation Dermatitis clinical trials

View clinical trials related to Radiation Dermatitis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05505214 Withdrawn - Clinical trials for Radiation Dermatitis

Topical Steroids & Bacterial Decolonization for Radiation Dermatitis

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether bacterial decolonization of the nares and skin, topical steroid therapy, or a combination of the two regimens prior to treatment with radiotherapy (RT) for breast and head and neck cancer patients can prevent grade 2 or higher grade radiation dermatitis (RD) graded via the Common Terminology Criteria for Adverse Events (CTCAE) scale and improve quality of life.

NCT ID: NCT04851522 Withdrawn - Clinical trials for Radiation Dermatitis

Dilute Bleach Compresses for Radiation Dermatitis

Start date: June 9, 2021
Phase: Early Phase 1
Study type: Interventional

This study is looking at the safety of applying dilute bleach compresses to patients receiving radiation therapy and the impact of these dilute bleach compresses on the frequency and severity of skin changes that occur during radiation therapy. The names of the study interventions involved in this study are: - Di-Dak-Sol: dilute bleach compresses - White petrolatum ointment

NCT ID: NCT04593914 Withdrawn - Clinical trials for Head and Neck Cancer

A Novel Skin Barrier Protectant for Acute Radiodermatitis

CASP-ORL
Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Acute radiodermatitis (ARD) is a distressing and painful skin reaction that occurs in 95% of the patients undergoing radiotherapy (RT). To date, there is still no general approved guideline for the prevention and management of acute radiodermatitis. The 3M™ Cavilon™ Advanced Skin Protectant is a novel skin barrier protectant that acts as a physical barrier against abrasion, moisture, and irritants. Moreover, it enables an environment for wound healing. The aim of this study is to evaluate the effectiveness of 3M™ Cavilon™ Advanced Skin Protectant in the prevention and management of ARD in patients with head and neck cancer.